Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 85,906 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Non Small Cell Lung Cancer, Metastatic NSCLC, Recurrent Non Small Cell Lung Cancer
Interventions: Pembrolizumab, GT103; Drug
Lead sponsor: Ryan Dackor; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Chicago, Illinois • Indianapolis, Indiana • Detroit, Michigan + 3 more

Conditions: Wound of Skin, Burns
Interventions: KeraStat® Gel with Morphine application, KeraStat® Gel application; Drug
Lead sponsor: The Metis Foundation; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Advanced Cancers
Interventions: Ilorasertib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Malignant Pleural Mesothelioma
Interventions: MORAb-009 (Amatuximab), Pemetrexed, Cisplatin; Drug
Lead sponsor: Morphotek; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 12
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more

Conditions: Coronavirus Disease 2019 (COVID-19)
Interventions: Rivaroxaban, Placebo, Standard of Care (SOC); Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 17
States / cities: Tucson, Arizona • Los Angeles, California • Oakland, California + 13 more

Conditions: Refractory Myelodysplastic Syndrome
Interventions: Actinium Ac 225 Lintuzumab, Bone Marrow Aspiration, Buccal Swab, Computed Tomography, Single Photon Emission Computed Tomography; Radiation · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-Active Secondary Progressive Multiple Sclerosis
Interventions: Foralumab TZLS-401 100 µg; Drug
Lead sponsor: Tiziana Life Sciences LTD; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Cytarabine, Echocardiography Test, Etoposide Phosphate, Mitoxantrone Hydrochloride, Multigated Acquisition Scan, Peposertib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 15
States / cities: Duarte, California • Los Angeles, California • Newport Beach, California + 11 more

Conditions: Metastatic Thyroid Gland Carcinoma, Unresectable Thyroid Gland Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Dabrafenib, Dabrafenib Mesylate, Echocardiography Test, Lapatinib, Lapatinib Ditosylate, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Vulvar Lichen Sclerosus
Interventions: Ablative Fractional 2940 nm Laser; Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sickle Cell Disease
Interventions: Deferoxamine, Deferasirox, Deferiprone, Echocardiography, Electrocardiogram (ECG); Drug · Device
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Fairfax, Virginia • Falls Church, Virginia

Conditions: Stiff Knee Gait, Brain Injuries
Interventions: placebo, botulinum toxin A (BTX-A); Drug
Lead sponsor: Mary Free Bed Rehabilitation Hospital; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: HIV Infections
Interventions: Atevirdine mesylate, Zidovudine; Drug
Lead sponsor: Pharmacia and Upjohn; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 12
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 9 more

Conditions: Healthy Subject
Interventions: SACT-1, EDURANT 25Mg Tablet; Drug
Lead sponsor: Aptorum International Limited; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Interventions: Best Practice, Exercise Counseling, Exercise Intervention, Medical Device Usage and Evaluation, Physical Performance Testing, Questionnaire Administration; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Asthma
Interventions: T-Piece Nebulizer, Breath-Enhanced Nebulizer, Albuterol, Pre-Treatment Spirometry Measurement, Post-Treatment Spirometry Measurement; Device · Drug · Procedure
Lead sponsor: Seton Healthcare Family; Other
Eligibility: 6 Years to 17 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Influenza, Human
Interventions: Flu shot text messages; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 74,811 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Danville, Pennsylvania • Philadelphia, Pennsylvania

Conditions: OCD
Interventions: escitalopram, Placebo ( sugar pill); Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pancreatic Cancer
Interventions: MM-141, Placebo, Gemcitabine, Nab-Paclitaxel; Drug
Lead sponsor: Merrimack Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 47
States / cities: Gilbert, Arizona • Anaheim, California • Fullerton, California + 40 more

Conditions: Influenza
Interventions: FluLaval® Quadrivalent, Fluzone®; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 35 Months
Enrollment: 316 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 12
States / cities: Sacramento, California • West Covina, California • Altamonte Springs, Florida + 9 more

Conditions: Dietary Intakes, Physical Activity, Child Care, Early Education, Children Aged 3-5 Years, Toddlers
Interventions: Boston Healthy Child Care Initiative; Other
Lead sponsor: Harvard School of Public Health (HSPH); Other
Eligibility: 2 Years to 5 Years
Enrollment: 456 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Breast Cancer
Interventions: Sacituzumab Govitecan-hziy, Eribulin, Capecitabine, Gemcitabine, Vinorelbine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 543 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 55
States / cities: Avondale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 40 more

Conditions: Endometrial Cancer, Endometrial Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Interventions: Mirvetuximab Soravtansine, Bevacizumab; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Pain, Post-Operative Pain, Third Molar Extraction
Interventions: Ibuprofen 600 mg Extended-Release Tablets, Placebo; Drug
Lead sponsor: SCOLR Pharma, Inc.; Industry
Eligibility: 16 Years to 45 Years
Enrollment: 256 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Salt Lake City, Utah

Search by objective public record fields.

Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer

Pilot Study: KeraStat® Gel for Topical Delivery of Morphine for Management of Non-Healing, Painful Open Wounds and Ulcers

Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors

An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma

A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection

Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment

Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis

Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia

Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

Laser Treatment for Vulvar Lichen Sclerosus

Early Screening and Treatment of Heart Complication in Sickle Cell Disease

Efficacy of Botulinum Toxin Injections in the Rectus Femoris to Treat Stiff Knee Gait Following Acquired Brain Injury

A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients

A Study of Bioavailability and Food Effect of SACT-1 and Edurant® Tablets in Healthy Adult Volunteers

Evaluation of a Couple-Based Physical Activity Intervention

Comparison of Breath-Enhanced and T-Piece Nebulizers in Children With Acute Asthma

Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates

Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder

A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer

Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age

Implementing Modified Practices to Leverage Evidence for Movement, Engagement, and Nutrition Topics in Early Childcare and Education

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer

Ibuprofen Extended-Release Dental Pain Study